Cocrystal Pharma, Inc.

Cocrystal Pharma, Inc. (www.cocrystalpharma.com) is a biotechnology company. The Company focuses on developing antiviral therapeutics that inhibit the essential viral replication function of RNA viruses causing acute and chronic viral diseases. The Company focuses on treating influenza virus, coronavirus, and norovirus infections by discovering and developing drug candidates targeting the viral replication process. The Company uses computational methods to screen and design product candidates using cocrystal structural information. The Company’s Hepatitis C Virus (HCV) Non-Nucleoside Polymerase Inhibitor CC-31244 is a pan-genotypic inhibitor of NS5B polymerase for the treatment of hepatitis C infection. The Company’s CC-42344 is a PB2 inhibitor for the treatment of influenza A infection. It has also developed chemical libraries consisting of non-nucleoside inhibitors, metal-binding inhibitors, and drug-like fragments.

• Cocrystal Pharma, Inc.